Clinical experiment designed to assess clinical efficacy targeting N/A in human patients. Primary outcome: cGAMP levels in spinal cord tissue
Analysis of spinal cord tissue samples from ALS" class="entity-link entity-disease" title="disease: ALS">ALS patients to measure levels of cyclic GMP-AMP (cGAMP), the specific metabolite produced by cGAS activation. This study aimed to validate the clinical relevance of cGAS/STING pathway activation in human ALS and establish cGAMP as a potential biomarker for mitochondrial DNA release and innate immune activation in ALS patients.
Measurement of cGAMP metabolite levels in post-mortem spinal cord samples from ALS" class="entity-link entity-disease" title="disease: ALS">ALS patients compared to controls
Elevated cGAMP levels in ALS" class="entity-link entity-disease" title="disease: ALS">ALS patient spinal cord samples
Significantly higher cGAMP levels in ALS" class="entity-link entity-disease" title="disease: ALS">ALS patients versus controls
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.